4.0 Article

The epidemiology of anal cancer

期刊

SEXUAL HEALTH
卷 9, 期 6, 页码 504-508

出版社

CSIRO PUBLISHING
DOI: 10.1071/SH12070

关键词

adenocarcinoma; homosexual; human papillomavirus; squamous cell carcinoma

资金

  1. CSL Biotherapies
  2. Merck
  3. National Health and Medical Research Council (NHMRC) [1016307, 571402, 1013353]
  4. NHMRC [568819, 568971]
  5. Australian Government Department of Health and Ageing
  6. National Health and Medical Research Council of Australia [568819] Funding Source: NHMRC

向作者/读者索取更多资源

Anal cancer comprises malignancies of the anal canal principally of two morphologic variants: squamous cell carcinoma (SCC) and adenocarcinoma. In most settings, SCC compromises more than 70% of cases. In the general population, anal cancer is uncommon, with age-standardised incidence rates mostly between 1 and 2 per 100 000 per year. However, incidence of anal SCC is increasing by 1-3% per year in developed country settings. High-risk human papillomavirus (HPV) types can be detected in 80-90% of all anal SCC cases, making it second only to cervical cancer in the closeness of its association with this virus. HPV-16 can be detected in similar to 90% of HPV-positive cases of anal SCC. Case-control studies have demonstrated that sexual risk factors (homosexuality in men and multiple sexual partners in women) are strongly associated with anal cancer risk. Other risk factors include immune deficiency and tobacco exposure. Anal cancer rates are highest in homosexual men, particularly in those who are HIV-positive, in whom anal cancer is among the most common of all cancers. Vaccination against HPV holds great promise for anal cancer prevention for those not already HPV-infected. For the current generation of adult high-risk populations, screening programs to allow early detection and treatment are under investigation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据